Holen Sie sich die Stockscreener-App
8.38
1.18%
-0.10
Handel nachbörslich:
8.32
-0.06
-0.72%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BHC?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$8.48
Offen:
$8.4
24-Stunden-Volumen:
1.11M
Relative Volume:
0.52
Marktkapitalisierung:
$3.08B
Einnahmen:
$9.47B
Nettoeinkommen (Verlust:
$-178.00M
KGV:
-3.1742
EPS:
-2.64
Netto-Cashflow:
$1.01B
1W Leistung:
-10.37%
1M Leistung:
+2.70%
6M Leistung:
+23.78%
1J Leistung:
+21.45%
1-Tages-Spanne:
$8.3619
$8.51
1-Wochen-Bereich:
$8.3619
$9.31
52-Wochen-Spanne:
$3.96
$11.46
Bausch Health Companies Inc Stock (BHC) Company Profile
Firmenname
Bausch Health Companies Inc
Sektor
Telefon
514-744-6792
Adresse
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Vergleichen Sie BHC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BHC | 8.38 | 3.08B | 9.47B | -178.00M | 1.01B | -2.64 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-20 | Hochstufung | Jefferies | Hold → Buy |
| 2023-06-16 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | Herabstufung | Truist | Buy → Hold |
| 2022-07-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-06-13 | Fortgesetzt | JP Morgan | Overweight |
| 2021-03-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-02-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-24 | Eingeleitet | Citigroup | Buy |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-02 | Eingeleitet | Goldman | Neutral |
| 2019-10-25 | Eingeleitet | Cowen | Outperform |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-15 | Hochstufung | TD Securities | Hold → Buy |
| 2019-07-19 | Eingeleitet | Wolfe Research | Outperform |
| 2019-06-11 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-01-02 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | Hochstufung | Piper Jaffray | Underweight → Neutral |
Alle ansehen
Bausch Health Companies Inc Aktie (BHC) Neueste Nachrichten
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug - Marketscreener.com
Herpes Zoster Oticus Market: Company Profiles, Segment Sizes, - openPR
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis - AccessWire
Bausch Health's Triple-Action Acne Treatment CABTREO Gains Key Canadian Approvals | BHC Stock News - StockTitan
Common Warts Treatment Market Trade Analysis and Statistical - openPR
Underactive Bladder Treatment Market Expected to Reach Huge - openPR
Genital Herpes Treatment Market Global Share, Trends, Business - openPR
Varicella Zoster (HHV-3) Infections Treatment Market Share, - openPR
Vitrectomy Devices Market is expected to reach US$ 2121.3 - openPR
22q11.2 Deletion Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas - The Globe and Mail
Actinic Keratosis Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyze | Bausch Health Companies, Sandoz Pharma, Athenex, Almirall, Vidac Pharma, G&E Herbal Biotech - Barchart
Periodontal Therapeutics Market to Grow at a Promising CAGR - openPR
Myopia and Presbyopia Treatment Market to Grow by USD 9.76 Billion from 2024-2028, as Rising Prevalence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Are Medical Stocks Lagging Bausch Health (BHC) This Year? - MSN
Body Contouring Treatments Market to Hit USD 2.58 Billion by 2029 with 10.0% CAGR | MarketsandMarkets™ - The Manila Times
Eye Health Supplements Market Trends and Growth Projections - openPR
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
189,000 Shares in Bausch Health Companies Inc. (NYSE:BHC) Bought by Intact Investment Management Inc. - MarketBeat
Bausch Health Companies' SWOT analysis: debt woes cloud strong Q3 stock performance - Investing.com
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales - MSN
Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Bausch Health secures $400 million loan amendment - Investing.com
Bausch Health secures $400 million loan amendment By Investing.com - Investing.com UK
Bausch Health Companies (NYSE:BHC) Price Target Raised to $11.00 at Royal Bank of Canada - MarketBeat
Bausch Health Companies Inc. (NYSE:BHC) Q3 2024 Earnings Call Transcript - Insider Monkey
Bausch Health Companies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Bausch Health stock outlook lifted as RBC cites robust Q3 growth and tax benefits - Investing.com
Traders Purchase High Volume of Bausch Health Companies Put Options (NYSE:BHC) - MarketBeat
Toronto Stocks Drop, Canada's GDP Flat in August; Bausch Health Rises on 3Q Beat - Marketscreener.com
Bausch Health Shares Rise on FY Outlook Upgrade, 3Q Beat - MarketWatch
Bausch Health Companies (NYSE:BHC) Trading 8.7% Higher on Better-Than-Expected Earnings - MarketBeat
Bausch Health Companies (TSE:BHC) Stock Price Up 8.4% Following Earnings Beat - MarketBeat
BHCBausch Health Companies Inc. Latest Stock News & Market Updates - StockTitan
Bausch: Q3 Earnings Snapshot - Houston Chronicle
Bausch Health Reports Growth Amid Improved Financials - TipRanks
Compared to Estimates, Bausch (BHC) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Bausch Health Companies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bausch Health Announces Third Quarter 2024 Results - AccessWire
Gastroparesis Treatment Market Top Trends and Growth Analysis: - openPR
Bausch Health Companies Q3 2024 Earnings Preview - MSN
Onychomycosis Treatment Market Size, Industry Analysis, - openPR
Actinic Keratosis Treatment Market Expected to Reach Huge - openPR
Canada Aesthetic Devices Market Size, Share, Industry Growth, - openPR
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking - Marketscreener.com
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence - StockTitan
TD COWEN Downgrades Bausch Health Companies (BHC) - MSN
Deal Dispatch: TKO Buys Bull Riding, Radford Motors Is BankruptApollo Global Management (NYSE:APO), Bausch Health Companies (NYSE:BHC) - Benzinga
Bausch Health Companies (NYSE:BHC) Lifted to "Buy" at StockNews.com - MarketBeat
FY2024 EPS Estimates for TSE:BHC Lifted by Zacks Research - MarketBeat
Finanzdaten der Bausch Health Companies Inc-Aktie (BHC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):